Clear guidance on prescription weight-loss treatment
For many British women, the late 40s and 50s bring both the greatest struggle with weight and the greatest hormonal turbulence. This guide examines how perimenopause and menopause interact with GLP-1 medication, and what questions to raise with a prescriber before starting.
A suppressed appetite changes more than your waistline — it reshapes how your household buys, cooks and throws away food. This practical guide helps UK patients plan their kitchen, shopping and batch-cooking habits for life on GLP-1 treatment.
Starting GLP-1 treatment often leaves Britain's kitchens stocked for an appetite that no longer exists. This practical guide walks through a room-by-room audit, from the overflowing freezer to the bulk-bought snack cupboard, and explains how to restock for smaller, protein-first portions without waste or guilt.
Prescription weight-loss medication doesn't just change appetites — it quietly rearranges the rituals built around them, from Sunday roasts to birthday cake. This reflective piece explores what patients lose, what they keep, and how to decline a second helping without declining the moment itself.
Men account for the majority of obesity-related hospital admissions in England, yet they form a small fraction of patients receiving GLP-1 prescriptions. We examine the cultural, clinical and commercial reasons behind the gap — and what finally prompts men to ask for help.
A GLP-1 prescription doesn't just change the patient — it reshapes the family kitchen. We look at how UK households are adapting mealtimes when one person has lost their appetite and everyone else still needs feeding, with practical strategies from a registered dietitian.
Rapid weight loss on GLP-1 medication does not distinguish between fat and muscle, and losing lean tissue quietly undermines metabolism, strength and long-term health. This guide explains why muscle matters, how to defend it through protein and resistance training, and the warning signs worth raising with your prescriber.
Taking your weight-loss medication on holiday requires more planning than packing a suitcase. This guide covers refrigeration, customs paperwork, time-zone scheduling and what to do if a pen goes missing mid-trip.
Vivid dreams, restless nights and mid-afternoon energy dips are among the least discussed effects reported by British patients starting GLP-1 medicines. We examine what the evidence says, when fatigue warrants a call to your prescriber, and how to time injections, meals and exercise for a better night's rest.
As GLP-1 prescriptions rise across Britain, more employees are managing weekly injections, side effects and appetite changes around shifts, meetings and commutes. This feature looks at disclosure, workplace stigma and the practical steps that keep treatment safe during working hours.
Weight loss is the headline, but GLP-1 receptor agonists interact with organs throughout the body. We review the documented benefits, the recognised risks and the MHRA warnings every UK patient should understand before starting treatment.
Patients tell us they can discuss dosage with a pharmacist more easily than with their own families. This opinion piece examines the stigma surrounding GLP-1 medication in Britain — and why silence can carry its own risks.
GLP-1 treatment doesn't just change appetite — it changes the contents of the trolley. We examine how UK patients' shopping habits shift on prescription weight-loss medication, what the new basket looks like, and how to keep it nutritious and affordable from Tesco to Aldi.
Millions of UK workers hold private medical insurance or workplace health schemes without realising what they cover. This guide explains how to interrogate your policy documents, approach your employer, and make the case for funding prescription weight-loss treatment.
When GLP-1 medication shrinks your appetite, every bite has to work harder. UK-registered dietitians explain why protein targets, portion strategy and nutrient density matter more than ever when you are eating considerably less.
Clinical trial data, MHRA Yellow Card reports and patient forums all tell a similar story: the first three months of GLP-1 treatment follow a predictable pattern of side effects. We rank them by frequency and severity, and explain when self-management is safe and when you should contact your prescriber.
Being turned down for GLP-1 medication at the GP surgery can feel like a door slamming shut, but the refusal usually has a specific, explainable reason. This guide unpacks the criteria behind the 'no' and maps out the legitimate routes still open to you.
The sticker price of Wegovy is only the beginning. We break down a full year of treatment across NHS, private clinic and online pharmacy routes — including the consultations and blood tests that quietly inflate the bill — and assess where paying extra genuinely buys better care.
Three injectable medications dominate the UK's medical weight-loss landscape, yet they differ considerably in how they work, what they cost and who they suit. This guide sets out the key differences so patients can approach a prescriber with informed questions.
Stopping a GLP-1 injection does not simply end treatment — it begins a physiological shift that many patients are unprepared for. Here is what the evidence says about weight regain, and the maintenance strategies UK clinicians now recommend.